company background image
603235 logo

JiangXi Tianxin Pharmaceutical SHSE:603235 Stock Report

Last Price

CN¥25.86

Market Cap

CN¥11.3b

7D

-4.8%

1Y

-6.8%

Updated

23 Aug, 2024

Data

Company Financials

JiangXi Tianxin Pharmaceutical Co., Ltd.

SHSE:603235 Stock Report

Market Cap: CN¥11.3b

603235 Stock Overview

Jiangxi Tianxin Pharmaceutical Co., Ltd. produces and sells vitamins in China.

603235 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance1/6
Financial Health6/6
Dividends2/6

JiangXi Tianxin Pharmaceutical Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for JiangXi Tianxin Pharmaceutical
Historical stock prices
Current Share PriceCN¥25.86
52 Week HighCN¥30.00
52 Week LowCN¥19.13
Beta0.39
11 Month Change-4.19%
3 Month Change-2.64%
1 Year Change-6.81%
33 Year Changen/a
5 Year Changen/a
Change since IPO-51.31%

Recent News & Updates

We Think JiangXi Tianxin Pharmaceutical (SHSE:603235) Can Stay On Top Of Its Debt

Aug 23
We Think JiangXi Tianxin Pharmaceutical (SHSE:603235) Can Stay On Top Of Its Debt

JiangXi Tianxin Pharmaceutical's (SHSE:603235) Weak Earnings May Only Reveal A Part Of The Whole Picture

May 06
JiangXi Tianxin Pharmaceutical's (SHSE:603235) Weak Earnings May Only Reveal A Part Of The Whole Picture

Does JiangXi Tianxin Pharmaceutical (SHSE:603235) Have A Healthy Balance Sheet?

Apr 24
Does JiangXi Tianxin Pharmaceutical (SHSE:603235) Have A Healthy Balance Sheet?

Recent updates

We Think JiangXi Tianxin Pharmaceutical (SHSE:603235) Can Stay On Top Of Its Debt

Aug 23
We Think JiangXi Tianxin Pharmaceutical (SHSE:603235) Can Stay On Top Of Its Debt

JiangXi Tianxin Pharmaceutical's (SHSE:603235) Weak Earnings May Only Reveal A Part Of The Whole Picture

May 06
JiangXi Tianxin Pharmaceutical's (SHSE:603235) Weak Earnings May Only Reveal A Part Of The Whole Picture

Does JiangXi Tianxin Pharmaceutical (SHSE:603235) Have A Healthy Balance Sheet?

Apr 24
Does JiangXi Tianxin Pharmaceutical (SHSE:603235) Have A Healthy Balance Sheet?

Shareholder Returns

603235CN Personal ProductsCN Market
7D-4.8%-5.5%-2.8%
1Y-6.8%-34.3%-18.4%

Return vs Industry: 603235 exceeded the CN Personal Products industry which returned -34.3% over the past year.

Return vs Market: 603235 exceeded the CN Market which returned -18.4% over the past year.

Price Volatility

Is 603235's price volatile compared to industry and market?
603235 volatility
603235 Average Weekly Movement4.1%
Personal Products Industry Average Movement4.6%
Market Average Movement5.6%
10% most volatile stocks in CN Market8.9%
10% least volatile stocks in CN Market3.7%

Stable Share Price: 603235 has not had significant price volatility in the past 3 months.

Volatility Over Time: 603235's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20042,471Zhongli Panwww.txpharm.com

Jiangxi Tianxin Pharmaceutical Co., Ltd. produces and sells vitamins in China. It offers products of vitamin B6, vitamin B9, folic acid, biotin, ascorbyl palmitate, and vitamin D3 for use as bulk pharmaceutical chemicals, food additives, and feed additives, as well as in other fields. The company was founded in 2004 and is based in Leping, China.

JiangXi Tianxin Pharmaceutical Co., Ltd. Fundamentals Summary

How do JiangXi Tianxin Pharmaceutical's earnings and revenue compare to its market cap?
603235 fundamental statistics
Market capCN¥11.29b
Earnings (TTM)CN¥514.80m
Revenue (TTM)CN¥1.80b

21.9x

P/E Ratio

6.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
603235 income statement (TTM)
RevenueCN¥1.80b
Cost of RevenueCN¥1.07b
Gross ProfitCN¥724.11m
Other ExpensesCN¥209.31m
EarningsCN¥514.80m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 31, 2024

Earnings per share (EPS)1.18
Gross Margin40.26%
Net Profit Margin28.63%
Debt/Equity Ratio5.1%

How did 603235 perform over the long term?

See historical performance and comparison

Dividends

1.9%

Current Dividend Yield

42%

Payout Ratio